Companies › MediLink Therapeutics (Suzhou)
7 active drug programs in 22 registered trials: 12 Phase 1, 6 Phase 3, 4 Phase 2; Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| YL202 EGFR-targeted therapy | – | Phase 3 | Locally Advanced or Metastatic Breast Cancer; Non-Small Cell Lung Cancer; NSCLC; Non Small Cell Lung Cancer … | Nov 2026 |
| YL201 B7H3-targeting antibody-drug conjugate | B7H3 | Phase 3 | Nasopharyngeal Carcinoma; Small Cell Lung Cancer; Advanced Esophageal Squamous Cell Carcinoma; SCLC, Extensive Stage … | Jan 2027 |
| Ivonescimab (AK112) Bispecific antibody targeting PD-L1 and CTLA-4 | PDCD1LG1, PDCD1LG2 | Phase 1 | Advanced Solid Tumors | Jan 2027 |
| YL205 | – | Phase 1 | Advanced Solid Tumors | Jul 2027 |
| YL217 | – | Phase 1 | Advanced Solid Tumor | Jul 2028 |
| YL242 | – | Phase 1 | Advanced Solid Tumor | Sep 2028 |
| YL211 | – | Phase 1 | Advanced Solid Tumors | Jun 2031 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06107686 | YL202 | Phase 2 | NSCLC | Oncology | Nov 2026 |
| NCT05653752 | YL202 | Phase 1 | Non Small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT07208773 | YL201 | Phase 1 | Advanced Solid Tumors | Oncology | Jan 2027 |
| NCT07208773 | Ivonescimab (AK112) | Phase 1 | Advanced Solid Tumors | Oncology | Jan 2027 |
| NCT07202364 | YL202 | Phase 2 | Non Small Cell Lung Cancer | Oncology | Jan 2027 |
| NCT06241846 | YL201 | Phase 2 | Metastatic Castration-resistant Prostate Cancer (mCRPC) | Oncology | Feb 2027 |
| NCT05434234 | YL201 | Phase 1 | Advanced Solid Tumor | Oncology | Apr 2027 |
| NCT06439771 | YL202 | Phase 2 | Locally Advanced or Metastatic Breast Cancer | Oncology | Jul 2027 |
| NCT06459973 | YL205 | Phase 1 | Advanced Solid Tumors | Oncology | Jul 2027 |
| NCT07169994 | YL202 | Phase 1 | Advanced Solid Tumors | Oncology | Nov 2027 |
| NCT06629597 | YL201 | Phase 3 | Nasopharyngeal Carcinoma | Oncology | Dec 2027 |
| NCT06612151 | YL201 | Phase 3 | Small Cell Lung Cancer | Oncology | Dec 2027 |
| NCT07461454 | YL202 | Phase 3 | Locally Advanced or Metastatic Breast Cancer | Oncology | Dec 2027 |
| NCT07258979 | YL201 | Phase 1 | Recurrent or Metastatic Nasopharyngeal Carcinoma | Oncology | Feb 2028 |
| NCT07487896 | YL201 | Phase 3 | Advanced Esophageal Squamous Cell Carcinoma | Oncology | Apr 2028 |
| NCT06859762 | YL217 | Phase 1 | Advanced Solid Tumor | Oncology | Jul 2028 |
| NCT07416994 | YL202 | Phase 3 | Non-Small Cell Lung Cancer | Oncology | Aug 2028 |
| NCT07197827 | YL242 | Phase 1 | Advanced Solid Tumor | Oncology | Sep 2028 |
| NCT06057922 | YL201 | Phase 1 | Advanced Solid Tumor | Oncology | Oct 2028 |
| NCT07407933 | YL201 | Phase 1 | Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma | Oncology | Nov 2028 |
| NCT07739758 | YL201 | Phase 3 | SCLC, Extensive Stage | Oncology | Jun 2029 |
| NCT06384352 | YL211 | Phase 1 | Advanced Solid Tumors | Oncology | Jun 2031 |
LaNova Medicines Servier Bio-Innovation Chipscreen Biosciences CSPC Megalith Biopharmaceutical IDEAYA Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.